The smoker's paradox after successful fibrinolysis: Reduced risk of reocclusion but no improved long-term cardiac outcome

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 4, 2009, Pages 385-393

  Kievit, Peter C ^a   Brouwer, Marc A ^a   Veen, Gerrit ^b   Aengevaeren, Wim R M ^a   Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiography; Fibrinolysis; Follow up studies; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PLACEBO; WARFARIN;

ADULT; ADVERSE OUTCOME; ANGIOGRAPHY; ARTERY REOCCLUSION; ARTICLE; BLOOD CLOT LYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SMOKING; SURVIVAL TIME; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS; SMOKING; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 67349200954     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0238-6     Document Type: Article

References (36)

1. Kannel WB (1981) Update on the role of cigarette smoking in coronary artery disease. Am Heart J 101:319-328. doi: 10.1016/0002-8703(81)90197-6
2. Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 309:901-911
3. Teo KK, Ounpuu S, Hawken S et al (2006) Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 368:647-658. doi: 10.1016/ S0140-6736(06)69249-0
4. Mueller HS, Cohen LS, Braunwald E et al (1992) Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 85:1254-1264
5. Barbash GI, Reiner J, White HD et al (1995) Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the smoker's paradox from the GUSTO-1 trial with angiographic insights. J Am Coll Cardiol 26:1222-1229. doi: 10.1016/0735-1097(95)00299-5
6. Grines CL, Topol EJ, O'Neil WW et al (1995) Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 91:298-303
7. TIMI Study Group (1985) The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312:932-936
8. Gomez MA, Karagounis LA, Allen A, Anderson JL, for the TEAM-2 investigators (1993) Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol 72:373-378. doi: 10.1016/0002-9149(93)91125-2
9. Zahger D, Cercek B, Cannon CP et al (1995) How do smokers differ from nonsmokers in their response to thrombolysis? (The TIMI-4 trial). Am J Cardiol 75:232-236. doi: 10.1016/0002-9149(95)80026-O
10. Angeja BG, Kermgard S, Chen MS et al (2002) The smoker's paradox: Insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis 13:133-139. doi: 10.1023/A:1020470721977
11. Lundergan CF, Reiner JS, McCarthy WF et al (1998) Clinical predictors of early-infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: The GUSTO-1 experience. J Am Coll Cardiol 32:641-647. doi: 10.1016/S0735-1097(98)00278-2
12. Ohman EM, Califf RM, Topol EJ et al (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 82:781-791
13. Brouwer MA, Böhncke JR, Veen G et al (1995) Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 26:1440-1444. doi: 10.1016/0735-1097(95)00355-X
14. Verheugt FWA, Meijer A, Lagrand WK et al (1996) Reocclusion: The flip side of coronary thrombolysis. J Am Coll Cardiol 27:766-773. doi: 10.1016/0735-1097(95)00492-0
15. Meijer A, Verheugt FWA, van Eenige MJ, Werter CJ (1994) Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling. Circulation 90:1706-1714
16. Brouwer MA, Kievit PC, Dieker HJ, Veen G, Karreman AJ, Verheugt FWA (2008) Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival. Observations from the APRICOT-trial. Am Heart J 155:1039-1046. doi: 10.1016/j.ahj.2008.01.008
17. Meijer A, Verheugt FWA, Werter CJ et al (1993) Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 87:1524-1530
18. Brouwer MA, Van den Bergh PJPC, Aengevaeren WRM et al (2002) Aspirin plus medium intensity coumadin versus aspirin alone in the prevention of reocclusion after successful thrombolysis for suspected acute myocardial infarction: Results of the APRICOT-2 study. Circulation 106:659-665. doi: 10.1161/01.CIR.0000024408.81821.32
19. ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-360
20. Reiber JHC, van der Zwet PMJ, Koning G et al (1993) Accuracy and precision of quantitative digital coronary arteriography: Observer-, short- and medium-term variabilities. Cathet Cardiovasc Diagn 28:187-198
21. Ambrose JA, Winters SL, Arora RR et al (1985) Coronary angiographic morphology in myocardial infarction: A link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 6:1233-1238
22. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682. doi: 10.1056/NEJM199309023291001
23. Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031-2037
24. The GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 357:1905-1914. doi: 10.1016/ S0140-6736(00)05059-5
25. The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615-1622. doi: 10.1056/NEJM199311253292204
26. Weisz G, Cox DA, Garcia E et al (2005) Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction-the smoker's paradox revisited. Am Heart J 150:358-364. doi: 10.1016/j.ahj.2004.01.032
27. Veen G, Meijer A, Verheugt FWA et al (1993) Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: Angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis. J Am Coll Cardiol 22:1755-1762
28. French JK, Ellis CJ, Webber BJ et al (1998) Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. Am J Cardiol 81:665-671. doi: 10.1016/ S0002-9149(97)01004-7
29. Kievit PC, Brouwer MA, Veen G, Karreman J, Verheugt FWA (2004) High-grade infarct related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction. Am Heart J 148:826-833. doi: 10.1016/j.ahj.2004.05.043
30. Topol EJ, Califf RM, George BS et al (1987) A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317:581-588
31. Barbash GI, White HD, Modan M et al (1993) Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the international tissue plasminogen activator/ streptokinase mortality trial. Circulation 87:53-58
32. Jaatun HJ, Sutradhar SC, Dickstein K (2004) Comparison of mortality rates after acute myocardial infarction in smokers versus non-smokers. Am J Cardiol 94:632-636. doi: 10.1016/j.amjcard.2004.05.029
33. Gibson CM, Karha J, Murphy SA et al (2003) Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 42:7-16. doi: 10.1016/S0735-1097(03)00506-0
34. Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A (2006) Percutaneous coronary intervention after fibrinolysis: A multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol 48:1326-1335. doi: 10.1016/j.jacc.2006.03.064
35. Wilson K, Gibson N, Willan A, Cook D (2000) Effect of smoking cessation on mortality after myocardial infarction. Meta-analysis of cohort studies. Arch Intern Med 160:939-944. doi: 10.1001/archinte.160.7.939
36. Critchley JA, Capewell S (2003) Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. A systematic review. JAMA 290:86-97. doi: 10.1001/jama.290.1.86